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Abstract
Background
SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in
eastern Africa, but is painful and requires hospitalization. Combination regimens including
AmBisome and miltefosine are safe and effective in India, but there are no published data
from trials of combination therapies including these drugs from Africa.
Methods
A phase II open-label, non-comparative randomized trial was conducted in Sudan and
Kenya to evaluate the efficacy and safety of three treatment regimens: 10 mg/kg single
dose AmBisome plus 10 days of SSG (20 mg/kg/day), 10 mg/kg single dose AmBisome
plus 10 days of miltefosine (2.5mg/kg/day) and miltefosine alone (2.5 mg/kg/day for 28
days). The primary endpoint was initial parasitological cure at Day 28, and secondary end-
points included definitive cure at Day 210, and pharmacokinetic (miltefosine) and pharma-
codynamic assessments.
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Results
In sequential analyses with 49–51 patients per arm, initial cure was 85% (95% CI: 73–92) in
all arms. At D210, definitive cure was 87% (95% CI: 77–97) for AmBisome + SSG, 77%
(95% CI 64–90) for AmBisome + miltefosine and 72% (95% CI 60–85) for miltefosine alone,
with lower efficacy in younger patients, who weigh less. Miltefosine pharmacokinetic data
indicated under-exposure in children compared to adults.
Conclusion
No major safety concerns were identified, but point estimates of definitive cure were less
than 90% for each regimen so none will be evaluated in Phase III trials in their current form.
Allometric dosing of miltefosine in children needs to be evaluated.
Trial Registration
The study was registered with ClinicalTrials.gov, number NCT01067443
Author Summary
Visceral leishmaniasis, or kala-azar, is a parasitic disease which is fatal without treatment.
A 17-day treatment of sodium stibogluconate (SSG) with paromomycin (PM) is the rec-
ommended treatment in eastern Africa, but requires painful injections, causes adverse
events, and patients need to stay in the hospital during treatment. An affordable, safe and
effective oral treatment would be preferable. Whilst research to identify entirely new drugs
is underway, existing treatments are being optimized as a short-term solution. Combina-
tion regimens based on AmBisome and miltefosine have been shown to be safe and effec-
tive in treating Indian patients, but there are no published data from use of these drugs in
combination regimens from Africa, where efficacy of treatments can be different from
India. Three regimens were evaluated for treating VL in eastern Africa, using AmBisome
in combination with SSG or miltefosine, or miltefosine alone. Once again, drugs which are
effective in India were found to be less so in African patients, and none of the regimes
tested showed sufficiently high definitive cure rates to evaluate in Phase III trials. The
results also suggest miltefosine was under-dosed in children and so allometric dosing,
which takes into account the differences in drug metabolism seen in children compared to
adults, needs to be studied.
Introduction
Visceral leishmaniasis (VL), caused by L. donovani, is a neglected disease in eastern Africa,
where it affects mostly the very poor. The disease burden is high, with an estimated 29,400 to
56,600 cases annually[1]. VL is fatal if left untreated, but with access to early diagnosis and
treatment the case fatality rate is low[2].
For decades, treatment with pentavalent antimonials (sodium stibogluconate-SSG) was the
first-line regimen in Africa despite a risk of cardiotoxicity, liver and pancreatic toxicity and 4
weeks of hospitalization [3]. A 17-day regimen of SSG in combination with paromomycin
(PM) demonstrated high efficacy six months post end of treatment in a Phase III trial (91%)
and is recommended as first line treatment in the eastern African countries, Sudan, South
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Sudan, Kenya, Uganda, Ethiopia, and Somalia [4,5]. Still, this short-course treatment is consid-
ered suboptimal in terms of route of administration, duration of treatment and potential
adverse drug reactions, and there is a need for new treatments.
An oral, safe, inexpensive, highly effective, short course treatment suitable for use in preg-
nancy is also urgently needed to control VL in the region [6], and research is currently under-
way to identify and evaluate potential new candidates. In the meantime, as a short-term
strategy, it was considered relevant to assess the efficacy of combination therapy with currently
available treatment options. Combination regimens are generally recommended on the basis of
potential additive or synergistic activity, increasing efficacy and allowing for shorter course
durations, in turn leading to increased compliance, shorter hospitalization and reduced drug
costs [6]. The rationale on the choice of drugs to combine is described below.
A short course of AmBisome (5mg/kg on day 1) plus miltefosine (2.5 mg/kg on days 2–8) in
India achieved six months cure in 98% (93–99%) of patients aged 6–58 years [7]. At the time of
this trial’s design, single and multiple doses of AmBisome were under evaluation in eastern
Africa. The recommended regimen of AmBisome monotherapy in Asia is 3-5mg/kg over 3–5
days (total dose of 15mg/kg) or 10mg/kg as single dose administration, whereas in eastern
Africa a total dose of 30mg/kg is needed to achieve satisfactory efficacy. On the other hand, to
make this combination treatment more field-adapted, one single administration of AmBisome
was proposed. A high dose and longer duration of AmBisome and miltefosine respectively
were needed in the region, however 10mg/kg AmBisome was considered to be the maximum
dose to be used as single administration due to safety concerns. Repeated doses of AmBisome
and longer duration of miltefosine would diminish treatment practicality, potentially impact
compliance and increase the cost of the regimen. AmBisome 10mg/kg was therefore considered
the appropriate option to be administered as a single dose in eastern Africa, in combination
with either miltefosine or SSG.
Miltefosine administered as a 28 day course of 2.5mg/kg/day achieved 94% (95% CI: 91–
97%) cure at six months post end of treatment in patients 12 years and above in India [9]. In a
subsequent study in Indian children aged 2–11 years, cure at six months was 94% (86–98%)
[10]. In HIV negative adult males (15 years and above) in Ethiopia, this regimen achieved
lower cure at six months in 89% (81–94%) of patients [11]. Most detailed pharmacokinetic
data for miltefosine came from a relatively healthy adult European patient group with cutane-
ous leishmaniasis [12]. While little is known about miltefosine pharmacokinetics in adult or
paediatric patients in general, no such data are available in African VL patients. Regional phar-
macokinetic data are needed to guide further dose optimization of miltefosine (combination)
therapy for VL in eastern Africa. SSG 10-day regimen was defined based on its well character-
ized efficacy in the region [4], to reduce hospitalization and improve the safety profile of the
treatment.
We report the results of a phase II randomized trial, conducted in Africa, to assess the safety,
efficacy and pharmacokinetic properties of two 11-day treatment regimens combining AmBi-
some with SSG and AmBisome with miltefosine, and a 28-day miltefosine monotherapy [13].
The hope was that at least one regimen would reach 90% efficacy at initial and definitive cure.
Methods
Trial design
The trial used a sequential design with a triangular continuation region [14]. The null hypothe-
sis was that the proportion cured at day 28 (p) is less than or equal to a value p0 which we set to
75%. The alternative hypothesis is that p>p0. If the upper boundary is crossed during an
interim analysis, then the null hypothesis is rejected and we conclude p>75%. Crossing the
Combination Therapies for VL in Eastern Africa
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004880 September 14, 2016 3 / 18
lower boundary at the time of an interim analysis implies that null hypothesis (proportion
cured75%) is not rejected and there is specified power to exclude a proportion cured of pa,
for which we chose a value of 90%. The type I error rate and power of the study were pre-speci-
fied as 5% and 95%, respectively (α = β = 0.05). Interim analyses were specified after every 15
patients in each arm. The maximum sample size per arm was 63.
Participants
Patients were recruited from Kimalel Health Centre in Kenya (Baringo district), and Dooka
and Kassab hospital (Gedaref State) in Sudan. These study sites are located in areas of stable
endemicity. Eligible patients were HIV negative, and aged between 7 and 60 years with parasi-
tologically confirmed VL who signed an informed consent (if aged 18y and over) or whom the
parent or legal guardian consented to participate in the study (if under 18y). The target popula-
tion was primary cases, so known relapse cases, or receipt of any anti-leishmanial drugs in the
previous 6 months, was an exclusion criterion. Other exclusion criteria were: severe protein
and/or caloric malnutrition defined as kwashiorkor or marasmus in children and BMI<15 in
adults; previous history of hypersensitivity reaction to SSG or amphotericin B; concomitant
severe infection such as TB or other serious underlying disease which would preclude evalua-
tion of patients response to the study medication; other conditions associated with splenomeg-
aly such as schistosomiasis; previous history of cardiac arrhythmia or an abnormal ECG;
Hb<5 g/dL; WBC<103/mm3; platelets<40,000/mm3, abnormal liver function tests (ALT and
AST) of more than three times the upper limit of the normal range, serum creatinine outside
the normal range for age and gender, and major surgical intervention within two weeks prior
to enrolment. Due to the potential teratogenicity of miltefosine, females of child bearing age
were also excluded.
Interventions
The three treatment regimens were as follows:
• AmBisome 10 mg/kg single dose (IV) on day 1 followed by 10 days of SSG (IM) 20 mg/kg
from day 2–11.
• AmBisome 10 mg/kg single dose (IV) on day 1 followed by 10 days of miltefosine 2.5mg/kg/
day (oral) from day 2–11 (up to a maximum dose of 150mg)
• Miltefosine 2.5 mg/kg/day (oral) from day 1–28 (up to a maximum dose of 150mg).
AmBisome (liposomal amphotericin B, 50 lyophilized powder in vials, Gilead Pharmaceuti-
cals, USA) was given as a single dose on day 1 at a dose of 10 mg/kg body weight, infused in 5%
dextrose over 1–2 hours. Miltefosine (Impavido, Zentaris) was provided as foil-wrapped blister
packs. The dose was calculated on a basis of 2.5 mg/kg body weight daily, up to a maximum of
150 mg. However, since 10 and 50 mg capsules were available, the actual doses given were:
30mg for 10-<14kg; 40mg for 14-<18kg; 50mg for 18-<22kg; 60mg for 22-<26kg; 70mg for
26-<30kg; 100mg for 30-<50kg and 150mg for 50kg. This resulted in a dose range of 2.0–
3.33 mg/kg/day of miltefosine. SSG (30 ml vials, each containing 100 mg/ml SSG, produced by
Albert David, India) was given as an intramuscular (IM) injection once daily, in a dose of 20
mg/kg body weight.
Rescue treatment was AmBisome 30 mg/kg Intravenously (IV) split into multiple doses
(according to country protocol) or SSG 20 mg/kg IM for 30–60+ days for patients not respond-
ing to initial rescue treatment or for patients requiring treatment for severe PKDL.
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Patients who did not meet inclusion criteria were offered free treatment outside the trial,
according to national treatment protocols [15]. All patients were offered counseling and
screening for HIV. Patients who tested positive were referred for appropriate treatment to the
national HIV control programme and treated according to national treatment guidelines, sur-
veillance and follow up according to the national protocol for HIV positive patients.
Outcomes
Two efficacy endpoints were defined. The primary endpoint was parasitological cure at Day 28
(initial cure), determined as absence of parasites on microscopy. This was used for interim
analysis decisions. Patients who died or required rescue before study treatment could be com-
pleted were considered initial treatment failures. The secondary endpoint was assessed at Day
210 (six months post end of treatment), representing final (or definitive) cure status. This was
defined as lack of VL signs and symptoms, and no requirement for rescue treatment during the
trial. Any patients with signs or symptoms of VL at any time during participation in the trial
underwent confirmatory parasitological testing.
Slow responders were defined as patients who had not cleared parasites at Day 28 (D28),
but who were clinically well, did not require rescue treatment at D28 and remained clinically
well throughout follow-up. These patients had a subsequent parasitological assessment at D56.
If microscopy was positive, the patient received rescue medication regardless of clinical presen-
tation. The treatment outcome was classified as failure from the time point rescue was
received.
Parasitological assessment by microscopy was done on lymph node aspirates (Dooka, Kas-
sab), spleen aspirates (Kimalel) or bone marrow samples (all sites). In Kimalel, 49 patients who
had unpalpable spleen on D28 had bone marrow aspirate while 27 patients had splenic aspi-
rate. Aspirates were smeared on two slides per sample, stained and graded according to the
standard logarithmic criteria.
Safety outcomes were the number (%) of patient experiencing a serious adverse event at any
time, frequency of adverse event within 60 days of treatment onset and an adverse drug reac-
tion (ADR) within 60 days.
Sample size
The study was designed and analyzed according to sequential methods, which have been devel-
oped to allow for discrete data analysis after a pre-specified number of patients are recruited.
The triangular test is one such method and uses straight line stopping boundaries [13]. The
continuation region is closed, which ensures a maximum sample size.
A minimum sample size of 30 per arm was imposed to allow for adequate PK assessment.
The trial was non-comparative and the sequential analysis was applied to each arm indepen-
dently, allowing them to potentially stop at different times.
Randomization
Subjects were randomly allocated using block randomization, stratified by site (Dooka, Kassab
and Kimalel). Site investigators were blinded to block size and codes were concealed in sealed
sequentially numbered, opaque envelopes under the control of the site investigator. The treat-
ing physician and patients were aware of the treatment given; miltefosine is oral medication
and AmBisome and SSG are administered intravenously (IV) and IV or intramuscularly (IM)
respectively. The laboratory technologists reading the slides were blind to treatment allocation.
Combination Therapies for VL in Eastern Africa
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Pharmacokinetics & pharmacodynamics
The pharmacokinetics of miltefosine were assessed in the two arms receiving miltefosine. In
the AmBisome + miltefosine arm human sodium heparin samples were nominally collected on
day 2, 4, 7, 11, 60, 210 (adults) or day 2, 7, 11, 60, 210 (children); and in the miltefosine mono-
therapy arm on day 1, 3, 7, 14, 21, 28, 60, 210 (adults) or day 1, 7, 14, 28, 60, 210 (children). On
the first day of miltefosine treatment, blood samples were drawn prior to the first dose, 4 hours
and 8 hours post first dose; whereas for all other time points blood samples were drawn prior
to the first miltefosine administration of that day. Samples were stored and transported frozen
at minimally -20°C until analysis. Sample preparation and miltefosine quantification were per-
formed using a validated liquid chromatography tandem mass spectrometry assay with a lower
limit of quantitation of 4 ng/mL (LC-MS/MS)[16]. End-of-treatment concentrations of milte-
fosine were compared with a Welch two sample t-test.
Repeated measurements of the Leishmania parasite load in whole blood were performed
using a qRT-PCR method targeting Leishmania kDNA. These pharmacodynamic samples
were collected from all participants in all three treatment arms prior to treatment and on Day
3, 7, 14, 28, 60, 210. DNA/RNA isolation was performed partially on site using a modified
Boom method [17], where silica samples were stored and transported at minimally -20°C until
the moment of further extraction and analysis. The qRT-PCR analysis was performed using a
Bio-Rad CFX-96 real-time machine (Bio-Rad, Veenendaal, the Netherlands). Parasite clear-
ance rates were calculated as relative decreases from baseline of all patients who had a detect-
able parasite load at baseline. A linear mixed-effects model was fitted in R using the maximum
likelihood method, with treatment day and arm as fixed effects and subject as a random effect.
Statistical analysis
Data analysis was performed using STATA, version 13 [18]. The primary analysis was by inten-
tion-to-treat (ITT).
Interim analyses were conducted once every 15 patients had reached D28 primary endpoint
assessment, using all available data and were based on the ITT analysis population. During
each interim analysis, triangular region tests were performed [14] and a decision was taken
whether to continue or stop recruitment in each arm based on the position of the test statistic
being within or outside the triangular region.
Once a decision was reached for each arm to stop, a point and interval estimate for the over-
all proportion cured at Day 28 (p) was obtained following Whitehead [19] based on all patient
data using the ITT analysis population.
The proportion of patients cured at day 210 is subject to sequential stopping as far as day 28, but
not thereafter. To take account of this, the probability of treatment success at D210 was estimated
by a probability tree argument, using the delta method for its standard error [20]. This method
takes account of the occurrence of slow response to treatment and relapse captured between D28
and D210. Relapse patients are those without detectable parasites at D28, but who develop signs
and symptoms of VL during the follow-up period and have a confirmatory parasitological diagnosis
anytime between D28 and D210. This analysis was based on the ITT analysis population.
A pre-specified subgroup analysis was to compare cure by sites using a χ2 or Fisher’s exact
test at D210, based on the ITT analysis population. Due to the relative geographical proximity
and small numbers, data from the Sudanese sites were combined, post hoc, to conduct the sub-
group analysis by country. Also, efficacy at Day 210 is compared by age groups split at 12
years, rather than the pre-specified 18 years.
All adverse events were coded to have lower level preferred term, higher level term and sys-
tem organ class classifications according to MedDRA, Version 12.0.
Combination Therapies for VL in Eastern Africa
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Safety outcomes were calculated as risk measures (number and percent of patients out of those
randomized) where patients with multiple AEs or ADRs were only counted once. The incidence of
ADRs was calculated as the number and percentage of patients experiencing each type of AE.
Ethical approval
Ethical approval was obtained from national and local Ethics Committees in Kenya and Sudan
prior to the start of the trial in each country. Ethical approval was also granted by LSHTM’s
Ethics Committee (#5543), and the Academic Medical Center Medical Ethics Committee
issued a 'declaration of no objection'. Study participants or their parents/guardians (for chil-
dren) gave a written signed informed consent before enrollment into the study.
The study was registered with ClinicalTrials.gov, number NCT01067443.
Results
Participants
A total of 151 patients were enrolled in the study (Fig 1). The most common reasons for exclu-
sion amongst patients with detectable parasites (n = 531) were age less than seven years (20.5%),
abnormal biological parameters (19.2%), being female of child bearing age (8.9%) and refusal of
consent (7.5%). Patients were recruited fromMay 2010 to Feb 2012. All patients remained hospi-
talized from screening until completion of D28 assessment. Follow up was completed in Oct
2012. The three arms appeared balanced with respect to baseline characteristics (Tables 1–4).
Analysis populations
Data from all 151 enrolled patients were available for the intention-to-treat analysis: 51 for the
AmBisome + SSG arm, 49 for the AmBisome + miltefosine arm and 51 for the miltefosine
monotherapy arm. There were four major protocol deviations. In three patients (one from
each treatment arm), body mass index at baseline was recorded as 15kg/m2. One patient in the
miltefosine monotherapy arm was discovered to have epilepsy and should also have been
excluded during screening due to severe concomitant condition.
Therefore, 147 patients were included in the per-protocol (PP) population, 50 for the AmBi-
some + SSG arm, 48 for the AmBisome + miltefosine arm and 49 for the miltefosine monother-
apy arm.
Interim analyses
The first and second interim analyses indicated that all arms should continue (Fig 2; Table 5).
The decision to stop recruitment was made after the third sequential analysis for promising
D28 efficacy in all three arms based on crossing the upper triangular boundary.
Initial response to treatment (D28 efficacy)
When accounting for the sequential trial design, cumulative efficacy at D28 was 85% (95% CI:
73%–92%) in all three arms (see Table 5). Results from the per protocol analysis were similar
to the ITT population.
Final cure at 6 months post end of treatment (D210 efficacy)
No patients were lost to follow up. One slow responder occurred in each treatment arm.
Relapse occurred in one, seven and eight patients in the AmBisome + SSG, AmBisome + Milte-
fosine and Miltefosine arms respectively. When accounting for the sequential trial design and
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change of status between D28 and D210, the D210 efficacy was 87% (95% CI: 77–97%) for the
AmBisome + SSG arm, 77% (95% CI: 64–90%) for the AmBisome + miltefosine arm and 72%
(95% CI: 60–85%) for the miltefosine arm (see Table 5).
Fig 1. Participant Flow.
doi:10.1371/journal.pntd.0004880.g001
Table 1. Baseline demographic characteristics.
AmBisome + SSG AmBisome + miltefosine Miltefosine
N = 51 N = 49 N = 51
Age (years) n (%) mean (SD) 15 (8) 14 (6) 15 (8)
7–17 35 (69) 35 (71) 37 (73)
18–60 16 (31) 14 (29) 14 (27)
Sex n (%) Female 14 (27) 9 (18) 5 (10)
Male 37 (73) 40 (82) 46 (90)
Site n (%) Dooka 19 (37) 18 (37) 20 (39)
Kassab 5 (10) 6 (12) 7 (14)
Kimalel 27 (53) 25 (51) 24 (47)
doi:10.1371/journal.pntd.0004880.t001
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Sub-group analysis
D210 cure was consistently lower in Sudan (Table 6) than in Kenya for each treatment, espe-
cially for the AmBisome + miltefosine arm (p = 0.074). The age distribution differed by country
with more younger patients recruited in Sudan; 49 (65%) Sudanese patients were aged less than
12 years compared to 25 (33%) Kenyan patients (chi-squared test p<0.0001). Age, as a possible
proxy for weight, could therefore be a realistic biological explanation for a difference in treat-
ment response by country, although additional differences in parasite susceptibility and host
factors cannot be excluded. In the present study population, age<12y was correlated with
Table 2. Baseline biological markers.
AmBisome + SSG AmBisome + miltefosine Miltefosine
N = 51 N = 49 N = 51
Weight mean (SD) 35.2 (14.5) 34.3 (13.4) 36.7 (13.4)
(kg) median (range) 31 (15–69) 30 (15–59) 31 (16–65)
Temperature mean (SD) 37.5 (1.1) 37.5 (1.1) 37.6 (1.3)
(°C) median (range) 37.3 (35.7–40) 37.5 (36–40.1) 37.6 (35.8–40.2)
Heart Rate mean (SD) 100.9 (10.6) 103 (13.7) 99.1 (11.4)
(beats/min) median (range) 100 (80–130) 100 (68–130) 100 (80–128)
Spleen Size mean (SD) 8.5 (4.4) 8.4 (5.6) 8.2 (3.9)
(cm) median (range) 8 (0–18) 7 (0–22) 8 (0–18)
Liver Size*** mean (SD) 2.3 (2.4) 2.5 (2.3) 2.7 (2.4)
(cm) median (range) 2 (0–10) 2 (0–8) 2 (0–10)
Systolic BP mean (SD) 100.9 (10.4) 95.7 (9.5) 99.4 (7.7)
(mm Hg) median (range) 100 (80–130) 90 (80–120) 100 (85–120)
Diastolic BP mean (SD) 62.2 (7) 61.2 (7.1) 63 (7.3)
(mm Hg) median (range) 60 (50–80) 60 (50–80) 60 (50–80)
Nutritional Status n (%) Severely underweight (BMI*< 15) 5 (10)** 9 (18)** 8 (16)**
Underweight (BMI 15–18.4) 23 (45) 18 (37) 16 (31)
Normal (BMI 18.5–24.9) 22 (43) 22 (45) 27 (53)
Obese/overweight (BMI > 24.9) 1 (2) 0 (0) 0 (0)
*BMI in kg/m2
**nutritional status categorization derived by post-hoc determination of WHO standardized value, as opposed to the BMI threshold in the severely
underweight exclusion criterion.
*** Liver size was measured below right costal margin
doi:10.1371/journal.pntd.0004880.t002
Table 3. Baseline parasite count.
AmBisome + SSG AmBisome + miltefosine Miltefosine
N = 51 N = 49 N = 51
Parasite Count Oil Immersion x100: n (%)
> 100,000/1000 (6+) 2 (4) 4 (8) 6 (12)
10,001–100,000/1000 (5+) 12 (24) 8 (16) 10 (20)
1,001–10,000/1000 (4+) 9 (18) 14 (29) 7 (14)
101–1,000/1000 (3+) 4 (8) 3 (6) 5 (10)
11-100/1000 (2+) 2 (4) 2 (4) 5 (10)
1-10/1000 (1+) 22 (43) 18 (37) 18 (35)
0 0 (0) 0 (0) 0 (0)
doi:10.1371/journal.pntd.0004880.t003
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weight<30kg. Therefore post-hoc stratified analyses were conducted by age group (<12 years,
12 years) and country. An age cut-off of 12 years was chosen based on the observed differ-
ences in drug exposure between those two groups. Cure rates were consistently lower in
patients aged less than 12 years in each arm in both countries (Table 6).
Safety
There were four SAEs, occurring in two patients in each of the AmBisome containing arms
(4% of patients randomised to each short-course arm; Table 7). Three patients discontinued
treatment.
One SAE in each AmBisome arm was a serious adverse drug reaction (SADR); in the AmBi-
some + SSG arm, severe anaemia resulted in death at day 20, and in the AmBisome + miltefo-
sine arm, renal failure at day 3 which was resolved. The two unrelated SAE were upper
respiratory tract infection and pneumonia. There were two deaths, one in each combination
arm. These were severe pneumonia in the AmBisome + Miltefosine arm which was considered
not related to study drug and severe anemia in the AmBisome + SSG arm which was consid-
ered possibly related.
The proportion of patients with at least one treatment emergent adverse event (TEAE) was
between 80 and 90% in each arm. The proportion of patients with at least one ADRs was
Table 4. Baseline laboratory parameters.
AmBisome + SSG AmBisome + miltefosine Miltefosine
N = 51 N = 49 N = 51
Haemoglobin mean (SD) 7.4 (1.8) 7 (1.3) 7 (1.3)
(g/dL) median (range) 7.3 (5–12.9) 6.9 (5–9.7) 6.8 (5–10.3)
White-cell Count mean (SD) 2.7 (1.3) 2.3 (1.2) 2.6 (1)
(x103/μL) median (range) 2.6 (1–7.4) 2.1 (1–5.5) 2.4 (1–5.2)
Platelets mean (SD) 130 (90) 101 (54) 114 (65)
(x103/μL) median (range) 104 (47–471) 88 (39–288) 100 (35–313)
AST mean (SD) 48 (25.9) 56.2 (31.7) 49 (29.9)
(U/L) median (range) 44 (8–112) 50 (3–115) 43.5 (3–117)
ALT mean (SD) 34.3 (20.5) 40.5 (27.1) 32.9 (20.7)
(U/L) median (range) 25 (2–87) 32 (4–102) 27.5 (7–102)
Creatinine mean (SD) 73.7 (26) 71.2 (24.7) 78 (21.2)
(μmol/L) median (range) 75 (35.4–129) 70.7 (26.5–114.9) 79 (35.4–132)
Blood urea nitrogen mean (SD) 5.7 (3.2) 5.8 (2.8) 5.7 (3.1)
(mmol/L) median (range) 5.3 (1.7–12.5) 6.1 (1.3–11.4) 5 (1.3–17.1)
Alkaline phosphatase mean (SD) 222 (196) 211 (157) 197 (117)
(U/L) median (range) 184 (10–1272) 169 (62–817) 176 (35–464)
Bilirubin mean (SD) 8.3 (4.8) 8.3 (4.6) 8.7 (5.2)
(total, mmol/L) median (range) 6.8 (2–27.4) 6.8 (1.7–22) 6.8 (3–27.4)
Sodium mean (SD) 137 (7) 135 (8) 134 (7)
(mmol/L) median (range) 137 (120–159) 136 (110–149) 133 (120–149)
Potassium mean (SD) 3.8 (0.4) 3.8 (0.4) 3.9 (0.4)
(mmol/L) median (range) 3.8 (2.9–4.6) 3.8 (2.9–4.6) 3.9 (2.8–4.9)
Magnesium mean (SD) 0.9 (0.3) 0.9 (0.2) 0.9 (0.2)
(mmol/L) median (range) 1 (0.2–1.9) 1 (0.2–1.6) 1 (0.4–1.5)
ALT: Alanine transaminase; AST: aspartate aminotransferase
doi:10.1371/journal.pntd.0004880.t004
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between 73 and 78% in each arm, while the proportion of patients with at least one AE not
related to study drug was between 33 and 45%.
Treatment was stopped in 1 patient due to a non-serious, moderate increase in serum creati-
nine and elevation of blood urea after 14 days of miltefosine monotherapy treatment. Two
patients in the AmBisome + miltefosine arm stopped treatment early (due to serious renal
insufficiency after 3 days of treatment and moderate non-serious increased blood creatinine
after 7 days).
Fig 2. Sequential stopping for the three arms. The horizontal axis (V) is proportional to sample size. The
vertical axis (Z) is the observed minus expected number of cures, so higher values are more favourable.
Each arm is shown by a line with three points representing, from left to right, the first interim analysis
(decision: continue for all arms), the second interim analysis (decision: continue for all arms) and the final
analysis. The final analysis (shown here) includes patients whose follow-up was still in progress at the time of
the third interim analysis, and confirmed the ‘stop’ decisions. Having all stopped at the same analysis, the
point estimates of proportion cured are the same for all arms (85%), as are the 95% confidence intervals (77–
97%). Based on the probability tree method, the point estimate at day 210 for AmBisome + SSG is 87% (95%
CI 77–97%); for AmBisome + Miltefosine it is 77% (64–90%) and for Miltefosine 72% (60–85%).
doi:10.1371/journal.pntd.0004880.g002
Table 5. Outcomes and events during treatment: Efficacy.
AmBisome + SSG AmBisome + Miltefosine Miltefosine
Interim analysis (D28: ITT) N Cured, n Decision N Cured, n Decision N Cured, n Decision
1 14 13 Continue 15 14 Continue 14 14 Continue
2 29 26 Continue 31 28 Continue 30 25 Continue
3 44 41 Stop 44 41 Stop 47 42 Stop
Cumulative analysis (D28) N Cured, n % (95% CI*) N Cured, n % (95% CI*) N Cured, n % (95% CI*)
ITT 51 47 85% (73–92) 49 46 85% (73–92) 51 45 85% (73–92)
Cumulative analysis (D210) N Cured, n % (95% CI*) N Cured, n % (95% CI*) N Cured, n % (95% CI*)
ITT 51 47 87% (77–97) 49 40 77% (64–90) 51 38 72% (60–85)
* Efﬁcacy and corresponding 95% CI estimated taking into account sequential design
doi:10.1371/journal.pntd.0004880.t005
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The median number of adverse effects experienced was two per patient for each arm. Of all
non-serious drug related events, three were severe and occurred in the miltefosine monother-
apy arm: two cases of anaemia and one case of gastro-intestinal pain. In the AmBisome + SSG
and in the AmBisome + miltefosine arms, all non-serious drug-related events were categorized
as mild to moderate.
Approximately 20% of patients in each arm treated with AmBisome experienced adverse
events during infusion, and approximately 20% of patients in each arm treated with miltefosine
vomited at least one dose. The overall occurrence of vomiting was 21% in all patients treated
with miltefosine. The occurrence of repeated vomiting of the same dose was relatively low (6%
of patients overall in both miltefosine arms). All treatment arms showed CTCAE grade 1 or
grade 2 aspartate aminotransferase increase (14–29%) and grade 1 hypomagnesaemia (14–
20%) (Table 8).
The only arm to contain SSG (combined with AmBisome) showed low levels of cardiac dis-
orders (<5%), similar to that of the AmBisome + MF arm. PKDL occurred in eight Sudanese
patients, 2 in the AmBisome+SSG arm, 1 in the AmBisome+Miltefosine arm and 5 in the mil-
tefosine monotherapy arm. All cases were mild or moderate and did not require treatment.
Table 6. Stratified D210 efficacy.
AmBisome + SSG AmBisome + Miltefosine Miltefosine
Country Sudan 21/24 (88%) 17/24 (71%) 18/27 (67%)
Kenya 26/27 (96%) 23/25 (92%) 20/24 (83%)
Fisher’s exact test p-value (2-sided) 0.331 0.074 0.211
Age Less than 12 years 22/25 (88%) 20/27 (74%) 13/22 (59%)
12 years and above 25/26 (96%) 20/22 (90%) 25/29 (86%)
Fisher’s exact test p-value (2-sided) 0.350 0.159 0.050
Sudan Less than 12 years 12/15 (80%) 13/19 (68%) 9/15 (60%)
12 years and above 9/9 (100%) 4/5 (80%) 9/12 (75%)
Kenya Less than 12 years 10/10 (100%) 7/8 (88%) 4/7 (57%)
12 years and above 16/17 (94%) 16/17 (94%) 16/17 (94%)
Data are number cured / number randomised (%). As estimates of cure rates, these percentages do not take into account the sequential design.
doi:10.1371/journal.pntd.0004880.t006
Table 7. Safety summary.
AmBisome + SSG AmBisome + Miltefosine Miltefosine
Number of patients 51 49 51
SAE, n (%) 2 (4) 2 (4) 0 (0)
SAE related to study drug, n (%) 1 (2) 1 (2) 0 (0)
Deaths, n (%) 1 (2) 1 (2) 0 (0)
TEAE, n (%) 41 (80) 44 (90) 46 (90)
TEADR, n (%) 37 (73) 38 (78) 40 (78)
Treatment stopped due to AE 0 (0) 2* (4) 1 (2)
AE during AmBisome infusion 11 (22) 9 (18) -
Vomited any scheduled dose, n (%) - 10 (20) 11 (22)
Repeatedly vomited the same scheduled dose - 1 (2) 2 (4)
Vomited more than one scheduled dose - 1 (2) 5 (10)
*Only one of these received rescue and is shown as such in the ﬂowchart.
TEAE: Treatment Emergent Adverse Event; TEADR: Treatment Emergent Adverse Drug Reaction
doi:10.1371/journal.pntd.0004880.t007
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Pharmacokinetics & pharmacodynamics
Miltefosine end of treatment concentrations were available for 42 patients from the AmBisome
+ miltefosine arm and for 45 patients from the miltefosine alone arm. Miltefosine keeps accu-
mulating until the end of treatment, so the end-of-treatment concentration (day 11 for the
AmBisome + miltefosine arm and day 28 for the miltefosine alone arm) is representative for
total exposure. The mean (SD) miltefosine concentration at the end-of-treatment was 16.47
(5.89) μg/mL for the AmBisome + miltefosine arm and 26.42 (8.66) μg/mL for the miltefosine
alone-arm. There were no significant differences in miltefosine end-of-treatment concentra-
tions between Sudanese and Kenyan patients. As depicted in Fig 3, patients with a body weight
Table 8. Incidence of adverse drug reactions.*
AmBisome + SSG AmBisome + Miltefosine Miltefosine
<12 years 12 years Total <12 years 12 years Total <12 years 12 years Total
23 28 51 24 25 49 20 31 51
BLOOD AND LYMPHATIC SYSTEM DISORDERS
ANAEMIA 2 (9%) 1 (4%) 3 (6%) 4 (17%) 0 (0%) 4 (8%) 5 (25%) 1 (3%) 6 (12%)
GASTROINTESTINAL DISORDERS
VOMITING 0 (0%) 1 (4%) 1 (2%) 8 (33%) 3 (12%) 11
(22%)
6 (30%) 7 (23%) 13
(25%)
GENERAL DISORDERS AND ADMINISTRATION
PYREXIA 8 (35%) 3 (11%) 11
(22%)
3 (13%) 2 (8%) 5 (10%) 3 (15%) 1 (3%) 4 (8%)
INVESTIGATIONS
ALANINE AMINOTRANSFERASE INCREASED 3 (13%) 2 (7%) 5 (10%) 1 (4%) 2 (8%) 3 (6%) 4 (20%) 5 (16%) 9 (18%)
ASPARTATE AMINOTRANSFERASE
INCREASED
6 (26%) 5 (18%) 11
(22%)
5 (21%) 2 (8%) 7 (14%) 6 (30%) 9 (29%) 15
(29%)
BLOOD ALKALINE PHOSPHATASE
INCREASED
4 (17%) 3 (11%) 7 (14%) 4 (17%) 0 (0%) 4 (8%) 3 (15%) 2 (6%) 5 (10%)
BLOOD CREATININE INCREASED 1 (4%) 4 (14%) 5 (10%) 1 (4%) 3 (12%) 4 (8%) 1 (5%) 2 (6%) 3 (6%)
BLOOD UREA INCREASED 4 (17%) 1 (4%) 5 (10%) 3 (13%) 3 (12%) 6 (12%) 1 (5%) 1 (3%) 2 (4%)
METABOLISM AND NUTRITION DISORDERS
HYPOKALAEMIA 1 (4%) 5 (18%) 6 (12%) 2 (8%) 3 (12%) 5 (10%) 0 (0%) 0 (0%) 0 (0%)
HYPOMAGNESAEMIA 4 (17%) 3 (11%) 7 (14%) 7 (29%) 0 (0%) 7 (14%) 5 (25%) 5 (16%) 10
(20%)
HYPONATRAEMIA 2 (9%) 1 (4%) 3 (6%) 3 (13%) 2 (8%) 5 (10%) 3 (15%) 0 (0%) 3 (6%)
RESPIRATORY, THORACIC ANDMEDIASTINAL DISORDERS
EPISTAXIS 5 (22%) 0 (0%) 5 (10%) 1 (4%) 1 (4%) 2 (4%) 2 (10%) 2 (6%) 4 (8%)
CARDIAC DISORDERS
ARRYTHMIA SUPRAVENTRICULAR 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (4%) 1 (2%) 0 (0%) 0 (0%) 0 (0%)
SINUS ARRYTHMIA 1 (4%) 1 (4%) 2 (4%) 3 (13%) 0 (0%) 3 (6%) 0 (0%) 0 (0%) 0 (0%)
SINUS BRADYCARDIA 0 (0%) 1 (4%) 1 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
INVESTIGATIONS
ELECTROCARDIOGRAM ABNORMAL 0 (0%) 0 (0%) 0 (0%) 1 (4%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 0 (0%)
RENAL AND URINARY DISORDERS
RENAL IMPAIRMENT 0 (0%) 0 (0%) 0 (0%) 1 (4%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 0 (0%)
RENAL FAILURE 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (4%) 1 (2%) 0 (0%) 0 (0%) 0 (0%)
* All events which occurred with more than 5% overall frequency, together with all cardiac disorders, and renal disorders.
Note: Causality assessment was based on investigator judgment. According to protocol all events that were not recorded as ‘Not Related’ were considered
‘Adverse Drug Reactions’
doi:10.1371/journal.pntd.0004880.t008
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<30 kg (n = 38, of which 97% aged12 yrs) were significantly less exposed to miltefosine than
patients with a higher body weight of30 kg (n = 49, of which 84% aged>12 yrs): for the
AmBisome + miltefosine arm the difference in end-of-treatment concentration was 36%
(p<0.0001) and for the miltefosine alone arm 32% (p<0.0001).
In total, for 77% of all patients there was a blood parasite load available at baseline, with var-
ious reasons for non-availability (e.g. no baseline sample available, issues with DNA extraction
or no parasite load detectable). Only the first week of treatment was taken into account to
assess the parasite clearance rate, since levels dropped to undetectable levels>1 week of treat-
ment for many patients. The effect of the treatment arm on the parasite clearance rate in the
first week of treatment was evaluated and is illustrated in Fig 4. The parasite clearance rate was
slower in the miltefosine alone arm compared to the AmBisome + miltefosine arm (p<0.0001),
while there was no significant difference between the two combination arms (p = 0.605). After
1 week of treatment, almost all individuals in both combination treatment arms had regressed
towards 0% parasite load, while the miltefosine monotherapy arm was on average still>10% of
the initial parasite load level (Fig 4).
A more extensive in-depth analysis of the pharmacokinetic and pharmacodynamics results
of this study will be reported elsewhere.
Fig 3. Comparison of the end-of-treatment miltefosine plasma concentrations between body weight categories. The left plot shows the AmBisome
+ miltefosine arm (10 days of miltefosine), the right plot the miltefosine alone arm (28 days of miltefosine).
doi:10.1371/journal.pntd.0004880.g003
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Discussion
This was the first phase II randomized trial of short course combination therapies containing
AmBisome for VL in Africa. Neither of the two AmBisome combinations (single daily dose of
AmBisome with 10 days of SSG or miltefosine) nor the 28 day miltefosine monotherapy (previ-
ously used in India) achieved more than 90% cure. There were no unexpected safety signals
detected in the trial, although there is very little power to detect unexpected events given the
small number of patients treated. Our recent study showed that multiple daily doses of 3 mg/kg
body weight of AmBisome maybe more beneficial to parasite clearance than a single 10 mg/kg
dose at day 1 [8], suggesting that a more frequent administration of AmBisome may result in
higher cure rates.
Pharmacodynamic data showed faster parasitic clearance with both AmBisome combina-
tions than with miltefosine monotherapy. Our study was not designed or powered to detect dif-
ferences in efficacy between adults and children, however patients with low body weight
(<30kg), almost all of whom were children under 12 years of age, were found to be significantly
underexposed to miltefosine compared to those with higher body weight, whether treated with
miltefosine alone or in combination with AmBisome.
The lack of efficacy compared to that seen previously in Southeast Asia, particularly with
regard to miltefosine, could be due to genetic diversity and differences in drug susceptibility
Fig 4. Parasite clearance from the blood in the first week of treatment. All parasite blood loads are relative to the individual parasite load at baseline.
The full lines indicate the mean and the error bars its 95% confidence interval, stratified per treatment arm.
doi:10.1371/journal.pntd.0004880.g004
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between east African and Indian Leishmania strains. However, results from Nepal and India
recently demonstrated a high relapse rate 6–12 months after miltefosine monotherapy (75–
90% efficacy), and more frequently in patients under the age of 15 years, suggesting a possible
drug underexposure effect [21,22]. Pharmacokinetic studies on miltefosine exposure in adults
and children from both countries show that the current 2.5 mg/kg/day miltefosine monother-
apy dose results in low exposure in children and that a proposed allometric dosing algorithm
could provide a higher and more optimal exposure in both adults and children [23]. Similar
lower drug exposure in children has been observed for antimonials (meglumine antmoniate) in
cutaneous leishmaniasis using a linear weight-adjusted dosage[24].
Our results confirmed a good tolerability of all treatments tested and no major safety con-
cerns were identified. Despite the higher exposure of miltefosine in adults, this does not seem
to be associated with higher safety risks. The frequency and severity of increase in creatinine
observed in this trial were not different from what had been already described.
In conclusion, as none of the treatment regimens tested achieved target efficacy they will
not be developed further. Miltefosine, as an oral drug treatment, is still of interest and so an
allometric dosing study is now underway to assess the safety and appropriate treatment dose of
miltefosine, particularly in children, in eastern Africa (NCT02431143).
This study highlights, once again, the difficulties faced when developing treatments for VL
in eastern Africa. In addition to improvements based on existing drugs, early drug discovery
efforts are ongoing, and several new chemical entities have been identified which will hopefully
give rise to safe, effective, oral treatments for the region in the future.
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